Neuroventi, Pharmcad and Autism Spectrum Disorder New Drug Joint Research Agreement

21-07-07

PharmCAD, a physics- and quantum-based artificial intelligence (AI) drug development company, signed a joint research agreement with Neuroventi, a brain development disorder drug development company, to discover and commercialize new drug candidates for autism spectrum disorders. He said on the 7th that he did.

Under this contract, PharmCAD uses the new drug development platform 'Pharmulator™' to discover new drug candidates that can bind to the target protein being studied by Neuroventi and provide them to Neuroventi.

Neuroventi is synthesizing selected substances and proving their efficacy in in vitro and in vivo experiments. plan.

Neuroventi is a brain development disorder treatment development company founded by professor Shin Chan-young (graduate school of medicine) at Konkuk University. We are focusing on prevention and treatment development.

CEO Shin is a scientist who has focused on research in the CNS field for the past 30 years, and is currently conducting preclinical research on candidate substances for complex action point iGluR inhibitors being developed as a treatment for autism.

Shin Chan-young, CEO of Neuroventi, said, “Autism is a disease in which complex factors such as genes and environment work, and there is no cure yet. “We expect to be able to develop an autism treatment with a high probability of success in a short period of time through signing a contract with Pharmcad.”

Kwon Tae-hyung, CEO of Pharmcad, said, “This agreement is a meaningful collaboration that harmonizes Neuroventi's know-how in autism treatment development research accumulated over many years and Pharmcad's differentiated AI-based innovative drug development capabilities. It will be a new opportunity for innovative new drug development with plans to verify the efficacy of the autism treatment target derived from Neuroventi's research results using the formular platform and quickly derive candidates with a high probability of success.”

Using a new drug development platform, Pharmcad is conducting research and development of various types of new drugs with pharmaceutical bio companies such as Huons, I-Gin, and Kainogen as well as its own pipeline, and through continuous partnerships with domestic and foreign research institutes, We are expanding our lines and business areas.